

**Antimicrobial susceptibility of *Flavobacterium psychrophilum* isolates
from the United Kingdom**

T P H Ngo¹, P Smith², K L Bartie¹, K D Thompson³, D W Verner-Jeffreys⁴, R Hoare¹, A
Adams¹

¹ Institute of Aquaculture, University of Stirling, Stirling, UK

² National University of Ireland, Galway, Ireland

³ Moredun Research Institute, Pentlands Science Park, Penicuik, UK

⁴ The Centre for Environment, Fisheries and Aquaculture Science, The Nothe,
Weymouth, UK

Correspondence: T P H Ngo, Institute of Aquaculture, University of Stirling, Stirling
FK9 4LA (e-mail: nhpthao.snn@tphcm.gov.vn)

This is the peer reviewed version of the following article: Ngo TPH, Smith P, Bartie KL, et al.
Antimicrobial susceptibility of *Flavobacterium psychrophilum* isolates from the United Kingdom.
Journal of Fish Diseases 2018;41:309–320, which has been published in final form at
<https://doi.org/10.1111/jfd.12730>. This article may be used for non-commercial purposes in
accordance With Wiley Terms and Conditions for self-archiving.

Abstract

Routine application of antimicrobials is the current treatment of choice for rainbow trout fry syndrome (RTFS) or bacterial coldwater disease (BCWD) caused by *Flavobacterium psychrophilum*. In this study, the antimicrobial susceptibilities of 133 *F. psychrophilum* isolates, 118 of which were from the UK, were evaluated by broth microdilution and disc diffusion methods following VET04-A2 and VET03-A guidelines of Clinical and Laboratory Standards Institute (CLSI), respectively. Isolates were categorised as wild type (fully susceptible, WT) or non-wild type (NWT) using normalised resistance interpretation (NRI) determined cut-off values (CO_{WT}). Broth microdilution testing showed that only 12% of UK isolates were WT to oxolinic acid ($MIC\ CO_{WT} \leq 0.25\text{ mg L}^{-1}$) and 42% were WT for oxytetracycline ($MIC\ CO_{WT} \leq 0.25\text{ mg L}^{-1}$). In contrast, all the isolates tested were WT ($MIC\ CO_{WT} \leq 2\text{ mg L}^{-1}$) for florfenicol, the main antimicrobial for RTFS control in the UK. Disc diffusion-based CO_{WT} values were $\geq 51\text{ mm}$ for 10 μg amoxicillin, $\geq 44\text{ mm}$ for 30 μg florfenicol, $\geq 30\text{ mm}$ for 2 μg oxolinic acid and $\geq 51\text{ mm}$ for 30 μg oxytetracycline. There was a high categorical agreement between the classifications of the isolates by two testing methods for florfenicol (100%), oxytetracycline (93%), and oxolinic acid (99%).

Keywords: *Flavobacterium psychrophilum*, antimicrobial susceptibility, epidemiological cut-off values, disc diffusion, broth microdilution, rainbow trout fry syndrome.

Introduction

Flavobacterium psychrophilum, a Gram-negative, filamentous, psychrotrophic bacterium, is the aetiological agent of rainbow trout fry syndrome (RTFS) and bacterial coldwater disease (BCWD), which was first described in USA in 1946 (Borg 1948). *F. psychrophilum* infection has been found throughout North America, Europe and elsewhere in Turkey, Australia, Peru, Japan and Korea (Barnes & Brown 2011). A commercial vaccine against RTFS/BCWD is still not available (Gómez *et al.* 2014). Although phage therapy (Stenholm *et al.* 2008; Kim *et al.* 2010a; Castillo *et al.* 2012) and the use of probiotic bacteria (StrömBesto & Wiklund 2011; Korkea-aho *et al.* 2011; Boutin *et al.* 2012; Burbank *et al.* 2012) have been suggested to be a promising alternative to the use of antibiotics in aquaculture, further studies are needed to prove the consistent effect of these green/blue technologies on preventing the infection of *F. psychrophilum*. Therefore, the use of antibiotics is currently the treatment of choice for controlling RTFS/BCWD outbreaks, resulting in a concern about the development of antimicrobial resistance by *F. psychrophilum* (Gómez *et al.* 2014). In the UK, three antibiotics (florfenicol, oxytetracycline and amoxicillin) are licensed for use in aquaculture by the UK Veterinary Medicines Directorate (VMD) (<http://www.vmd.defra.gov.uk/>).

Several studies have examined the antimicrobial susceptibility of *F. psychrophilum* isolated from the USA (Pacha 1968, Soule *et al.* 2005; Van Vliet *et al.* 2017), the UK (Rangdale *et al.* 1997; Verner-Jeffreys & Taylor 2015; Smith *et al.* 2016), Denmark (Lorenzen *et al.* 1997; Bruun *et al.* 2000; Dalsgaard & Madsen 2000; Schmidt *et al.*

2000; Bruun *et al.* 2003; Smith *et al.* 2016), France (Michel *et al.* 2003), Japan (Izumi & Aranishi 2004), Turkey (Kum *et al.* 2008; Durmaz *et al.* 2012; Boyacioğlu & Akar 2012; Boyacioğlu *et al.* 2015), Canada (Hesami *et al.* 2010), Spain (Del Cerro *et al.* 2010), Norway (Nilsen *et al.* 2011), Chile (Henríquez-Núñez *et al.* 2012; Miranda *et al.* 2016) and Finland (Sundell *et al.* 2013). However, differences in the medium and growth conditions used in these studies and variations in the interpretive criteria used make comparisons difficult. In addition, some of these studies included only a small number of isolates, while others produced susceptibility data that was too diverse to allow any estimate of cut-off values to interpret their meaning.

Smith *et al.* (2013) addressed the need for standardised and internationally recognized protocols for laboratory *in vitro* susceptibility testing in monitoring and surveillance programmes and the use of standardised methods to calculate epidemiological cut-off values for interpretation of the meaning of the data collected in such surveys.

The aim of the present study was to evaluate the antimicrobial susceptibility of 140 *F. psychrophilum* isolates, 125 of which were obtained within the UK, by the disc diffusion and standardised broth microdilution methods following VET03-A (CLSI 2006) and VET04-A2 (CLSI 2014a) guidelines respectively, as recommended by the Clinical and Laboratory Standards Institute (CLSI) for aquatic bacteria with an optimal growth temperature below 35°C.

Materials and Methods

Bacterial isolates and growth conditions

A total of 140 *F. psychrophilum* isolates, previously described by Ngo *et al.* (2017) for genetic and serological diversity, were examined in this study. This collection comprised 125 isolates obtained within the UK during 2005-2015 and 15 isolates from other countries (France, Denmark, Finland, Ireland, Chile and the USA) (Table 1 and 2); *F. psychrophilum* isolates were obtained from rainbow trout (*Oncorhynchus mykiss*), 16 from Atlantic salmon (*Salmo salar*) and one from coho salmon (*O. kisutch*). *F. psychrophilum* type strain NCIMB 1947^T (ATCC 49418^T) was included for comparative purposes. For all the experiments, the *F. psychrophilum* isolates were grown in Modified Veggietone (MV) medium [veggitones GMO-free soya peptone (Oxoid, UK), 5 g L⁻¹; yeast extract (Oxoid, UK), 0.5 g L⁻¹; magnesium sulphate heptahydrate (Fisher chemicals, UK), 0.5 g L⁻¹; anhydrous calcium chloride (BHD), 0.2 g L⁻¹; dextrose (Oxoid, UK), 2 g L⁻¹; agar (solid medium; Oxoid, UK), 15 g L⁻¹; pH 7.3] at 18°C for 72 – 96 h. Broth cultures were shaken at 140 rpm. Stock cultures were maintained at -70°C in tryptone–yeast extract–salts medium supplemented with glucose [FLP – tryptone (Oxoid, UK), 4.0 g L⁻¹; yeast extract, 0.4 g L⁻¹; anhydrous calcium chloride, 0.2 g L⁻¹; magnesium sulphate heptahydrate, 0.5 g L⁻¹; D(+)-glucose (Sigma, UK), 0.5 g L⁻¹; Cepeda *et al.* 2004] with 10% glycerol and on Protect-Multi-purpose cryobeads (Technical Service Consultants Ltd, UK).

The 125 isolates from 27 sites within the UK in this study had been isolated between 2005 and 2015 with the majority (110 strains, 88%) being retrieved between 2011 and 2013. Among these isolates, 51 genotypes and 7 plasmid profiles were detected

(Ngo *et al.* 2017) (Table 1). However, within this set of 125 isolates, there were five groups of two or three isolates that were recorded as having the same site, sampling time point, genetic profiles and susceptibilities. In order to avoid the over-representation, 7 potential replicates were eliminated from the analysis and only 118 UK isolates were included in the analyses. The epidemiological cut-off values were calculated from the data obtained from 118 UK isolates and 15 isolates from other countries. The frequencies of NWT phenotypes circulating the UK during 2005 – 2015 were estimated from the analysis of 118 isolates.

Minimum inhibitory concentration (MIC) testing

The MICs for *F. psychrophilum* isolates were performed using Sensititre CMP1MSP plates (Trek Diagnostic Systems; ThermoScientific.com/microbiology). These test plates were 96-well, dry-form plates that contained twofold serial dilutions of the following antimicrobial agents: ampicillin (AMP) 0.03–16 mg L⁻¹, amoxicillin (AMOX) 0.25–16 mg L⁻¹, erythromycin (ERY) 0.25–128 mg L⁻¹, enrofloxacin (ENRO) 0.002–1 mg L⁻¹, florfenicol (FFN) 0.03–16 mg L⁻¹, flumequine (FLUQ) 0.008–4 mg L⁻¹, ormetoprim/sulphadimethoxine (PRI) 0.008/0.15–4/76 mg L⁻¹, oxolinic acid (OXO) 0.004–2 mg L⁻¹, oxytetracycline (OTC) 0.015–8 mg L⁻¹ and trimethoprim/sulphamethoxazole (SXT) 0.015/0.3–1/19 mg L⁻¹.

The MIC assays were determined using the broth microdilution protocol recommended for *F. psychrophilum* in the CLSI guideline VET04-A2 (CLSI 2014a).

Colony counts on inoculum suspensions were performed to ensure that the final inoculum density was close to 5.0×10^5 colony-forming units (CFU) per millilitre.

Disc diffusion testing

Disc diffusion susceptibility of the *F. psychrophilum* strains was determined by the protocol suggested in the guideline VET03-A (CLSI 2006) with modification on the agar percentage of the culture medium. It should be noted, however, that this protocol has not been formally accepted as a standard by CLSI. The test was performed on diluted Mueller-Hinton medium (Sigma-Aldrich, UK; 3 g L⁻¹) containing 1.5% agar (Agar No. 1, LP0011, Oxoid, UK) (MHA) and 5% foetal calf serum (FCS; Gibco, Fisher chemicals, UK) and plates were incubated at 15°C for 68 – 72 h. Antimicrobial agent discs (Oxoid, Basingstoke, UK) containing 10 µg amoxicillin (AMOX₁₀), 5 µg enrofloxacin (ENRO₅), 30 µg florfenicol (FFN₃₀), 2 µg oxolinic acid (OXO₂), 30 µg oxytetracycline (OTC₃₀) and 25 µg trimethoprim/sulphamethoxazole (SXT₂₅) were employed.

Quality control

As specified in VET04-A2 (CLSI 2014a) the quality control strain *Escherichia coli* NCIMB 12210 (ATCC[®] 25922) was included in every MIC test run and was assayed on diluted CAMHB at 18°C as described above. However, no quality control ranges have been established for any disc diffusion protocol specifying these incubation conditions

(CLSI 2006). Therefore, the *F. psychrophilum* type strain NCIMB 1947^T was also included in every test run to monitor the performance of the method.

Statistical analysis

The antimicrobial susceptibility patterns of 133 *F. psychrophilum* isolates used in this study were analysed by application of protocol and species-specific epidemiological cut-off values (CO_{WT}). These values allow isolates to be categorised as fully susceptible (wild type, WT) or manifesting reduced susceptibility (non-wild type, NWT). In this work, CO_{WT} values were calculated for both the MIC and disc diffusion data by the normalised resistance interpretation (NRI) method (Kronvall 2003; 2010). This NRI method was used with permission from the patent holder, Bioscand AB, TÄY, Sweden (European patent No 1383913, US patent No 7,465,559).

MIC distributions were analysed using the NRI method of Kronvall (2010). A fully automatic Excel spreadsheet for performing these NRI analyses is available on-line (<http://www.bioscand.se/nri/>). In data sets where a small percentage (<5 %) of the WT observations were “below-scale”, these observations were treated as having the MIC value immediately below the limit of the plate quantitation. When the percentage of the WT observations “below-scale” was >5%, the data set was considered as unsuitable for NRI analysis (Smith *et al.* 2016).

The NRI analyses for zone histograms were performed using a modification of the standardised protocol developed by Kronvall & Smith (2016). In this modification, the

peak values of the zone sizes for the putative WT isolates were established using 8-point rather than 4-point rolling means.

Terminology

The acronyms ECV and ECOFF have been used by the CLSI and European Committee on antimicrobial susceptibility testing (EUCAST) respectively for epidemiological cut-off values set from data generated in multiple laboratories. In the present study, the term CO_{WT}, as previously employed by Smith *et al.* (2016), was used to indicate epidemiological cut-off values that have not been set by either of these international agencies. It has been suggested that the terms resistant and sensitive should not be used to refer to the categories identified by epidemiological cut-off values (Silley 2012). Following this suggestion, when isolates are categorised by epidemiological cut-off values, the terms wild type (WT) and non-wild type (NWT) should be used for fully susceptible isolates and isolates exhibiting reduced susceptibility respectively.

Results

Quality control

The MIC values obtained with the quality control reference strain *E. coli* NCIMB 12210, grown at 18°C for 72-96 h in diluted CAMHB, were within the acceptable range published by CLSI in VET03/04-S2 guideline (CLSI 2014b). All the inoculum suspensions used in MIC tests were confirmed to have the density ranging from 4.8×10^5 to 5.3×10^5 CFU mL⁻¹ by colony counts.

F. psychrophilum type strain NCIMB 1947^T was included in all disc diffusion tests and the inhibition zone data of this strain were 56 – 72 mm for AMOX₁₀, 60 – 75 mm for ENRO₅, 57 – 64 mm for FFN₃₀, 64 – 86 mm for OTC₃₀, 45 – 56 mm for OXO₂ and 16 – 44 mm for SXT₂₅. The mean of the ranges of these zone sizes for these six agents against the *F. psychrophilum* type strain was 16.5 ± 7.6 mm.

NRI analysis of susceptibility data

The distribution of MIC values of 133 *F. psychrophilum* isolates for ten antimicrobial agents is shown in Table 3 and 4. MIC-based CO_{WT} values of antimicrobial agents are presented in Table 5. The distribution of disc diffusion zones of the isolates for six antimicrobials is presented in Figure 1 and the zone data-based CO_{WT} values of antimicrobial agents are shown in Table 6.

Oxytetracycline

MIC data for OTC showed a clear bimodal distribution (Table 3). The modal group with lower MICs was assumed to represent the WT group. NRI analysis calculated the standard deviation of the log₂ normalised WT distribution as 0.68 and a CO_{WT} value of ≤ 0.25 mg L⁻¹ (Table 5). Applying this cut-off, fifty-six (42%) of the 133 isolates analysed were categorised as WT.

The disc diffusion zone sizes for OTC₃₀ showed considerable diversity at the high zone end (Figure 1A). However, NRI analysis of these data identified a high zone modal group with a standard deviation of 7.44 mm. If this modal group was assumed to

represent zones obtained from WT isolates, a provisional CO_{WT} value of ≥ 51 mm could be calculated (Table 6). Applying this cut-off, sixty-five (49%) of the 133 isolates analysed were categorised as WT.

The categorisation of isolates resulting from applying the cut-off of ≤ 0.25 mg L⁻¹ to the MIC data agreed with the categorisation resulting from applying the disc zone cut-off of ≥ 51 mm to the zone data for 93% of the 133 isolates studied (Figure 2A).

Amoxicillin and ampicillin

For AMOX, 98 observations (100% of the lower MIC modal observations) and for AMP, 24 observations (24% of the lower MIC modal observations) were recorded as “below-scale” (Table 3). On this basis, neither of these data sets was considered suitable for NRI analysis.

As in MIC data set for AMP there was a clear separation of the low MIC and high MIC modal groups, this data set was considered suitable for estimating CO_{WT} by visual examination. The estimated value generated by this subjective method was ≤ 0.125 mg L⁻¹ for AMP. A scatterplot of the paired MIC data for these two beta-lactam agents (Figure 3A) suggested a high correlation between them and also demonstrated that AMOX might have the same distribution as AMP.

The disc diffusion zone sizes for AMOX₁₀ were also bimodal (Figure 1B). NRI analysis of these data calculated a standard deviation of the normalised WT distribution of 5.2 mm and a CO_{WT} value of ≥ 56 mm (Table 6). A scatterplot of the paired MIC

values versus inhibition zone sizes for amoxicillin suggested a high correlation between them (Figure 2B).

Florfenicol

MIC data for FFN showed a clear unimodal distribution (Table 3). This modal group was assumed to represent the WT isolates. NRI analysis calculated a standard deviation of the \log_2 normalised WT distribution of 0.68 and a CO_{WT} value of $\leq 2 \text{ mg L}^{-1}$ (Table 5).

The disc diffusion zone sizes for FFN₃₀ were also unimodal (Figure 1C). NRI analysis of these data calculated a standard deviation of the normalised WT distribution of 5.6 mm and a CO_{WT} value of $\geq 45 \text{ mm}$ (Table 6).

Applying the cut-off of $\leq 2 \text{ mg L}^{-1}$ to the MIC data and the disc zone cut-off of $\geq 41 \text{ mm}$ to the zone data categorised 100% of the 133 isolates studied as WT (Figure 2C).

Oxolinic acid, Flumequine and Enrofloxacin

The MIC values of OXO, FLUQ and ENRO were bimodally distributed (Table 3). NRI analysis calculated the standard deviation of the \log_2 normalised WT distribution as 0.67, 0.57 and 0.74 for OXO, FLUQ and ENRO respectively. The MIC CO_{WT} values calculated from these data were $\leq 0.25 \text{ mg L}^{-1}$ for OXO, $\leq 0.125 \text{ mg L}^{-1}$ for FLUQ and $\leq 0.032 \text{ mg L}^{-1}$ for ENRO (Table 5). When these CO_{WT} values were applied, 21 (16%), 20 (15%) and 20 (15%) of the 133 isolates were categorised as WT with respect to OXO, FLUQ and ENRO respectively.

Scatterplots of the MIC data for OXO against those for FLUQ and ENRO (Figure 3B and 3C) demonstrated a high (>97.7%) categorical agreement in both cases. This suggests that it would be safe to accept MIC data for OXO as a predictor of reduced susceptibility to the FLUQ and ENRO (Smith *et al.* 2016). Adoption of this proposal would reduce the cost of routine susceptibility testing.

The disc diffusion zone sizes for OXO₂ were bimodal (Figure 1D). NRI analysis of these data calculated a standard deviation of the normalised WT distribution of 8.5 mm. This high standard deviation is probably a result of the fact that high zone modal group was diverse and composed of only a few observations. This suggests that the disc CO_{WT} value calculated by NRI analysis of ≥ 30 mm (Table 6) should only be treated as a provisional value. Applying the cut-off of ≤ 0.25 mg L⁻¹ to the MIC data for OXO and the disc zone cut-off of ≥ 30 mm to the zone data resulted in 99% agreement in the categorisation of the 133 isolates studied (Figure 2D).

The disc diffusion zone sizes for FLUQ were not determined and those for ENRO did not show any visually obvious high zone modal group and were not subject to NRI analysis (Figure 1E).

Erythromycin

MIC values of ERY had a unimodal distribution. NRI analysis calculated a standard deviation of the log₂ normalised WT distribution of 0.98 and the CO_{WT} value was calculated as ≤ 8 mg L⁻¹ (Table 3 and 5). This value determined that all 133 *F. psychrophilum* isolates analysed were WT for ERY.

Ormetoprim/Sulphadimethoxine and Trimethoprim/Sulphamethoxazole

The distributions of the MIC values for these two potentiated sulfonamide agents were diverse but appeared to be unimodal (Table 3). NRI analysis generated provisional CO_{WT} values for PRI and SXT of ≤ 320 mg L⁻¹ and ≤ 160 mg L⁻¹, respectively. However, the standard deviations calculated for the normalized distribution of these putative WT observations, $1.39 \log_2$ mg L⁻¹ and $1.67 \log_2$ mg L⁻¹ for PRI and SXT respectively, were higher than those recorded for all other agents in this work (Table 5). Therefore, the validity of these CO_{WT} values was questionable.

The disc diffusion zone sizes for SXT did not show any visually obvious high zone modal group and were not subject to NRI analysis (Figure 1F).

Discussion

Data precision

Precision of MIC data sets

The precision of any CO_{WT} value is a function of the precision of the observational data used to calculate it. Smith *et al.* (2012) demonstrated that the standard deviations of the normalised distributions of the log₂ WT observation calculated by the NRI analysis could provide a proxy measurement of precision. The median of the standard deviation calculated for 22 *F. psychrophilum* data sets published by Michel *et al.* (2003), Smith *et al.* (2016) and Van Vliet *et al.* (2017) was $0.70 \log_2$ mg L⁻¹. In this work, the median value of standard deviations calculated for ENRO, ERY, FFN, FLUQ, OTC and OXO

(Table 5) was $0.72 \log_2 \text{ mg L}^{-1}$. This suggests that the MIC data sets obtained in this work for these agents were of an acceptable level of precision and were of sufficient quality that they could be used to calculate CO_{WT} values.

The standard deviations calculated for potentiated sulphonamide MIC data, $1.39 \log_2 \text{ mg L}^{-1}$ and $1.61 \log_2 \text{ mg L}^{-1}$ for PRI and SXT respectively in this work, were, however, considerably larger and were taken to indicate significant imprecision. Smith *et al.* (2016) and Van Vliet *et al.* (2017), who used the same testing protocol as was used in this work also reported very low precision in the MIC data they obtained for these agents (mean $1.43 \log_2 \text{ mg L}^{-1}$). Due to their low precision, it was considered that valid CO_{WT} could not be established for PRI and SXT data obtained in this work.

Precision of disc diffusion data sets

Smith & Kronvall (2015) analysed zone data for reference control strains *E. coli* ATCC 25922 and *Aeromonas salmonicida* ATCC 33658 and demonstrated a reduction in precision as the incubation temperature decreased and time increased. Analysis of the data obtained from the reference strain *F. psychrophilum* NCIMB 1947^T and from the test isolates in this work suggest a similar effect of temperature and time on precision of zone size data.

The mean of the ranges of zone sizes for the control reference strain *E. coli* NCIMB 12210 provided in the guideline VET03-A (CLSI 2006) for tests performed at 35°C, 28°C and 22°C were $7.7 \pm 0.8 \text{ mm}$, $8.0 \pm 1.5 \text{ mm}$ and $11.8 \pm 2.0 \text{ mm}$ respectively (Smith

and Kronvall 2015). In this work, the mean range obtained at 15°C for six agents against the control strain *F. psychrophilum* NCIMB 1947^T was 16.5 mm ± 7.6 mm

The mean of standard deviations of the 19 zone data sets obtained at 28°C in studies of *Edwardsiella tarda* and *Vibrio harveyi* was 2.53 mm (Lim *et al.* 2016). For 13 data sets of *A. salmonicida* obtained at 22°C, the mean was 3.9 mm (Miller & Reimschuessel 2006; Smith *et al.* 2007). In this work, the disc diffusion assays were performed at 15°C and the mean standard deviation of the normalised distributions of the four disc data sets was 6.7 mm.

These comparisons suggest that the low precision of the zone data sets obtained in this work was most probably a function of the inherent property of this type of assay rather than any laboratory specific errors in the performance of the assays. However, the low level of precision suggests that any CO_{WT} calculated from these zone data should be treated as only provisional estimates.

Categorical agreements

With the calculated MIC CO_{WT} and provisional disc diffusion-based CO_{WT} of FFN, OXO and OTC, it is possible to calculate the percentage agreement between the categorisation of the 133 isolates obtained by analysing the observed MIC measures and the zone size data. The values of these categorical agreements were 100% for FFN, 99% for OXO and 93% for OTC. This high level of categorical agreement raise the possibility that, although the disc diffusion protocol used in this work generated data of low precision, the

provisional CO_{WT} calculated from them may have some value in detecting isolates of reduced susceptibility.

It should, however be noted that Smith & Kronvall (2015) demonstrated that reduced temperatures and prolonged incubation time increased not only the level of intra-laboratory variation but also the level of inter-laboratory variation in the data generated. High inter-laboratory variation of the data will have the consequence that although any provisional disc CO_{WT} calculated in one laboratory may have some value in interpreting zone data produced in that laboratory, it may be misleading if applied to zone data obtained in another laboratory. In other words, the CO_{WT} values for MIC data calculated in this work are probably laboratory-independent and of general or ‘universal’ applicability. However, it is probably safer to treat the CO_{WT} values for inhibition zone data generated in this work as only of local applicability. As a consequence, each laboratory using this protocol to perform disc diffusion assays would have to generate their own CO_{WT} values. The disc diffusion test protocol used in this work has not been accepted as a standard by CLSI. It is possible that further optimisation such as using a higher incubation temperature (18°C) may lead to a protocol with increased precision.

Comparison of CO_{WT} values calculated for MIC measures determined by standardised broth microdilution protocols of CLSI for *F. psychrophilum*

The values for any CO_{WT} are protocol-specific. It is, therefore, legitimate to compare the CO_{WT} calculated in this work with those published by Smith *et al.* (2016) and Van Vliet *et al.* (2017), who also used the standardised broth microdilution protocol (CLSI 2014a)

and NRI method to calculate CO_{WT} for *F. psychrophilum* from MIC data. This comparison can be made with respect to three agents (FFN, OXO and OTC). For FFN and OXO, the same CO_{WT} values (≤ 2 mg L⁻¹ and 0.25 mg L⁻¹ respectively) were calculated from all three studies. For OTC, Smith *et al.* (2016) and Van Vliet *et al.* (2017) calculated a CO_{WT} of ≤ 0.125 mg L⁻¹ compared to the 0.25 mg L⁻¹ calculated in this work. It should, however, be noted that in this work, no isolates were recorded as manifesting an MIC of 0.25 mg L⁻¹ for OTC (Table 3) and the categorisation of the 133 isolates studied here would be the same if either CO_{WT} value was applied to them. This agreement in the CO_{WT} values calculated illustrates the value of the use of standardised test protocols and statistically based interpretive criteria and suggests that it should be possible for CLSI to set internationally applicable, laboratory-independent ECVs for this species.

Frequencies of UK *F. psychrophilum* isolates with reduced susceptibility

Applying the CO_{WT} values calculated or, in the case of AMP, estimated in this work (Table 5) to the MIC data from these 118 UK *F. psychrophilum* isolates, the frequencies of those with reduced susceptibility were 92% for FLUQ, 90% for ENRO, 88% for OXO, 58% for OTC, 32% for AMP and no isolates were recorded with reduced susceptibility for FFN and ERY. However, as noted by Smith *et al.* (2016), ERY, a drug whose primary value is in treating infections by gram-positive bacteria, has never been recommended for the control of *F. psychrophilum* infections of aquatic animal. There have been two earlier studies of NWT frequencies in UK *F. psychrophilum* isolates. Rangdale *et al.* (1997)

investigated the susceptibility of 47 *F. psychrophilum* isolates, 36 of which were collected in the UK. However, their MIC data sets were of very low precision (mean log₂ standard deviation for FFN, OTC and OXO of 3.24 log₂ mg L⁻¹) and therefore, reliable estimates of NWT frequencies could not be assessed. In a smaller study (27 UK *F. psychrophilum* isolates) that used the same testing protocol and statistically based interpretive criteria as used in this work, Smith *et al.* (2016) reported NWT frequencies similar to those reported here. When the isolates studied here are combined those studied by Smith *et al.* (2016), the frequency of NWT phenotypes in the 145 UK isolates obtained during 2005 – 2015 were 85%, 59% for OXO and OTC respectively, and no NWT phenotypes were reported for FFN.

Antibiotic use in UK rainbow trout farming

Verner-Jeffreys & Taylor (2015) reported the use of four agents (FFN, OXY, AMOX and OXO) in attempts to control RTFS in the UK. The survey revealed that FFN was the treatment of choice in the industry. These FFN treatments were generally considered very effective. Where other antimicrobials (OTC, OXO or AMOX) were used, the therapeutic response was reported as either mixed or poor.

These anecdotal reports of comparative treatment efficacies reflect closely the frequencies with which isolates of reduced susceptibility were detected in this work. This in turn suggests that routine susceptibility testing, associated with appropriate interpretation of these data obtained, would be cost-effective and an essential element in the prudent use of antibiotics in aquaculture.

Verner-Jeffreys & Taylor (2015) reported that within the UK most batches of rainbow trout were treated with FFN at least once during every production cycle. Thus, given the relatively high frequency of NWT phenotypes detected with respect to the alternative agents available (OXO, OTC and AMOX), it would appear that, as it currently operates, the UK rainbow trout industry is critically dependent on the continued clinical efficacy of FFN. Some concern must be expressed about the long-term sustainability of an industry that would be affected by the emergence of strains of *F. psychrophilum* that were clinically resistant to this agent.

As FFN is the agent of choice to treat *F. psychrophilum* infection in many countries, it is reasonable to postulate that this critical dependence of the continued clinical efficacy of FFN is not unique to the UK but is wide-spread in the global trout farming industry. The global situation with respect to FFN susceptibility of *F. psychrophilum* can be assessed from a number of studies that have been published. Studies that have employed standard MIC testing protocols and that generated data of adequate precision have been reported from Denmark and the UK (Smith *et al.* 2016), Chile (Miranda *et al.* 2016) and USA (Van Vliet *et al.* 2017). Studies of the antimicrobial susceptibility of Danish (Bruun *et al.* 2000) and French (Michel *et al.* 2003) *F. psychrophilum* isolates that used non-standardised agar dilution protocols have also been published. Combining the data presented in these studies with the data generated in this study provides a total of 829 measurements of FFN susceptibility, of which only two (0.2%), both collected in Chile, were categorised as NWT with respect to FFN. Recently the presence of a region containing resistance genes to florfenicol (*floR*), tetracycline (*tetX*), streptothricin and

chloramphenicol acetyltransferase gene was detected in *Chryseobacterium* spp. from rainbow trout (Verner-Jeffreys *et al.* 2017). However, this resistance gene cassette was not widely distributed in Flavobacteriaceae isolates (Verner-Jeffreys *et al.* 2017).

These data would indicate, rather surprisingly, that the selective pressure that must have resulted from the use of this agent during the 25 or more years since the introduction of the antibiotic to aquaculture (Smith 2008) has not yet resulted in any significant emergence of strains of *F. psychrophilum* strains with reduced susceptibility to this agent. However, it cannot be automatically assumed that this situation will continue. Given the significance of FFN to the global trout farming industry, and as recommended by the World Animal Health Organisations (<http://www.oie.int/international-standard-setting/aquatic-code/access-online>), it is essential that programmes designed to detect any emergence of isolates of *F. psychrophilum* with reduced susceptibility to this agent are implemented as a matter of urgency by all relevant authorities.

Conclusions

Interpretation of MIC data by NRI analysis for *F. psychrophilum* generated by the standardised microdilution protocol (CLSI 2014a) provided an overview of the frequencies of isolates manifesting reduced susceptibility in 118 UK isolates. There was a general agreement between the frequencies of isolates manifesting WT phenotypes for the agents FFN, OXO and OTC, observed in this work, and the reports of their clinical success when used in commercial farms in the UK. On the basis of this, it is strongly recommended that, in order to ensure rational and prudent use of antibiotics to control *F.*

psychrophilum infections, susceptibility testing using standardised methods should be performed in association with all on-farm administrations of the antibiotics.

The Aquatic Animal Health Code of the World Animal Health Organisation recommends that all relevant authorities should implement programmes for the monitoring and surveillance of the susceptibility of aquatic animal pathogens to antibiotics used in their areas. As the UK trout farming industry is critically dependent on the continued efficacy of FFN in the control of RTFS, the implementation of such a programme with respect to *F. psychrophilum* would appear to be a priority for the UK. The standardised MIC susceptibility testing protocol of CLSI and the epidemiological cut-off values developed in this work would provide the analytical methods for such a programme.

Acknowledgements

This work was supported by the EU project TARGETFISH, Targeted Disease Prophylaxis in European Fish Farming, under FP7 (grant no. 311993). Special thanks are expressed to Dr Robin Wardle from MSD Animal Health for generously donating Sensititre CMP1MSP plates; Mr Richard Hopewell from Dawnfresh Farming, Dr Tim Wallis from Ridgeway Biologicals, Dr Matthijs Metselaar from Fish Vet Group and Dr Margaret Crumlish from the Bacteriology laboratory, University of Stirling for providing clinical *F. psychrophilum* strains.

References

469 Baquero F. (1990) Resistance to quinolones in gram-negative microorganisms:
470 mechanism and prevention. *European Urology* **17**, 3-12.

471 Barnes M.E. & Brown M.L. (2011) A review of *Flavobacterium psychrophilum* biology,
472 clinical signs, and bacterial cold water disease prevention and treatment. *The Open Fish*
473 *Science Journal* **4**, 40-48.

474 Bauer A.U., Kirby W.M., Sherris J.C. & Track M (1966) Antibiotic susceptibility testing
475 by a standardized single disc method. *Journal of Clinical Pathology* **45**, 493–494.

476 Borg A.F. (1948) Studies on myxobacteria associated with diseases in salmonid fishes.
477 Ph.D. Thesis. University of Washington. Seattle.

478 Boutin S., Bernatchez L., Audet C. & Derôme N. (2012) Antagonistic effect of
479 indigenous skin bacteria of brook charr (*Salvelinus fontinalis*) against *Flavobacterium*
480 *columnare* and *F. psychrophilum*. *Veterinary Microbiology* **155**, 355-361.

481 Boyacioglu M. & Akar F. (2012) Isolation of *Flavobacterium psychrophilum* causing
482 rainbow trout fry syndrome and determination of an effective antibacterial treatment in
483 rainbow trout (*Oncorhynchus mykiss*) fry. *Kafkas Üniversitesi Veteriner Fakültesi*
484 *Dergisi* **18**, 197-203.

485 Boyacıoğlu M, Kum C., Kirkan S., Sekkin S., Parin U., Karademir U. & Akar F. (2015)
486 Comparison of *in vitro* and *in vivo* antibacterial efficacy for the control of
487 *Flavobacterium psychrophilum* in rainbow trout (*Oncorhynchus mykiss*) fry: the first
488 genotypical evidence in West Aegean region of Turkey. *Turkish Journal of Veterinary*
489 *and Animal Sciences* **39**, 314-321.

490 Bruun M.S., Schmidt A.S., Madsen L. & Dalsgaard I. (2000) Antimicrobial resistance
491 patterns in Danish isolates of *Flavobacterium psychrophilum*. *Aquaculture* **187**, 201-212.

492 Bruun M.S., Madsen L. & Dalsgaard I. (2003) Efficiency of oxytetracycline treatment in
493 rainbow trout experimentally infected with *Flavobacterium psychrophilum* strains having
494 different in vitro antibiotic susceptibilities. *Aquaculture* **215**, 11-20.

495 Burbank D., LaPatra S., Fornshell G. & Cain K. (2012) Isolation of bacterial probiotic
496 candidates from the gastrointestinal tract of rainbow trout, *Oncorhynchus mykiss*
497 (Walbaum), and screening for inhibitory activity against *Flavobacterium*
498 *psychrophilum*. *Journal of Fish Diseases* **35**, 809-816.

499 Castillo D., Higuera G., Villa M., Middelboe M., Dalsgaard I., Madsen L. & Espejo R.
500 (2012) Diversity of *Flavobacterium psychrophilum* and the potential use of its phages for
501 protection against bacterial cold water disease in salmonids. *Journal of Fish Diseases* **35**,
502 193-201.

503 Cepeda C. & Santos Y. (2000) Rapid and low-level toxic PCR-based method for routine
504 identification of *Flavobacterium psychrophilum*. *International Microbiology* **3**, 235-238.

505 CLSI (2006) *Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated*
506 *from Aquatic Animals*, Approved Guideline VET03-A. Clinical and Laboratory Standards
507 Institute, Wayne, PA.

508 CLSI (2008) *Development of In-Vitro Susceptibility Testing Criteria and Quality Control*
509 *Parameters for Veterinary Antimicrobial Agents: Approved Guideline – third edition*,
510 CLSI document M37-A3. Clinical and Laboratory Standards Institute, Wayne, PA.

511 CLSI (2014a) *Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated from*
512 *Aquatic Animals, Approved Guideline VET04-A2*. Clinical and Laboratory Standards
513 Institute, Wayne, PA.

514 CLSI (2014b) *Performance Standards for Antimicrobial Susceptibility Testing of*
515 *Bacteria Isolated from Aquatic Animals; Second Informational Supplement*. CLSI
516 document VET03/04-S2. Clinical and Laboratory Standards Institute, Wayne, PA.

517 Dalsgaard I. & Madsen L. (2000) Bacterial pathogens in rainbow trout, *Oncorhynchus*
518 *mykiss* (Walbaum), reared at Danish freshwater farms. *Journal of Fish Diseases* **23**, 199-
519 209.

520 Del Cerro A., Márquez I. & Prieto J.M. (2010) Genetic diversity and antimicrobial
521 resistance of *Flavobacterium psychrophilum* isolated from cultured rainbow trout,
522 *Onchorynchus mykiss* (Walbaum), in Spain. *Journal of Fish Diseases* **33**, 285-291.

523 Durmaz Y., Onuk E.E. & Çiftci A. (2012) Investigation of the presence and antibiotic
524 susceptibilities of *Flavobacterium psychrophilum* in rainbow trout farms (*Oncorhynchus*
525 *mykiss* Walbaum, 1792) in The Middle and Eastern Black Sea Regions of Turkey.
526 *Ankara Üniversitesi Veteriner Fakültesi Dergisi* **59**, 141-146.

527 Gao P., Mao D., Luo Y., Wang L., Xu B. & Xu L. (2012) Occurrence of sulphonamide
528 and tetracycline-resistant bacteria and resistance genes in aquaculture environment.
529 *Water Research* **46**, 2355-2364.

530 Gómez E., Méndez J., Cascales D. & Guijarro J.A. (2014) *Flavobacterium*
531 *psychrophilum* vaccine development: a difficult task. *Microbial Biotechnology* **7**, 414-
532 423.

533 Grape M., Farra A., Kronvall G. & Sundström L. (2005) Integrons and gene cassettes in
534 clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. *Clinical*
535 *Microbiology and Infection* **11**, 185-192

536 Henríquez-Núñez H., Evrard O., Kronvall G. & Avendaño-Herrera R. (2012)
537 Antimicrobial susceptibility and plasmid profiles of *Flavobacterium psychrophilum*
538 strains isolated in Chile. *Aquaculture* **354-355**, 38-44.

539 Hesami S. & Parkman J. (2010) Antimicrobial susceptibility of *Flavobacterium*
540 *psychrophilum* isolates from Ontario. *Journal of Aquatic Animal Health* **22**, 39-49.

541 Izumi S. & Aranishi F. (2004) Relationship between *gyrA* mutations and quinolone
542 resistance in *Flavobacterium psychrophilum* isolates. *Applied and Environmental*
543 *Microbiology* **70**, 3968-3972.

544 Kim J.H., Gomez D.K., Nakai T. & Park S.C. (2010a) Isolation and identification of
545 bacteriophages infecting ayu *Plecoglossus altivelis altivelis* specific *Flavobacterium*
546 *psychrophilum*. *Veterinary Microbiology* **140**, 109-115.

547 Korkea-aho T., Heikkinen J., Thompson K., von Wright A. & Austin B. (2011)
548 *Pseudomonas* sp. M174 inhibits the fish pathogen *Flavobacterium psychrophilum*.
549 *Journal of Applied Microbiology* **111**, 266-277.

550 Kronvall G. (2003) Determination of the real standard distribution of susceptible strains
551 in zone histograms. *International Journal of Antimicrobial Agents* **22**, 7-13.

552 Kronvall G., Kahlmeter G., Myhre E. & Galas M.F. (2003) A new method for normalized
553 interpretation of antimicrobial resistance from disk test results for comparative purposes.
554 *Clinical Microbiology and Infection* **9**, 120-132.

555 Kronvall G. (2010) Normalized resistance interpretation as a tool for establishing
556 epidemiological MIC susceptibility breakpoints. *Journal of Clinical Microbiology* **48**,
557 4445-4452.

558 Kronvall G. & Smith P. (2016). Normalized resistance interpretation, the NRI method.
559 Review of NRI disc test applications and guide to calculations. *ACTA Pathologica*,
560 *Microbiologica et immunologica Scandinavica* **124**, 1023-1030.

561 Kum C., Kirkan S., Sekkin S., Akar F. & Boyacioglu M. (2008) Comparison of *in vitro*
562 antimicrobial susceptibility in *Flavobacterium psychrophilum* isolated from rainbow trout
563 fry. *Journal of Aquatic Animal Health* **20**, 245-251.

564 Lim Y-J., Kim D-H., Roh H.J., Park M-A., Park C-I. & Smith P. (2016) Epidemiological
565 cut-off values for disc diffusion data generated by standard test protocols from
566 *Edwardsiella tarda* and *Vibrio harveyi*. *Aquaculture International*. DOI 10.1007/s10499-
567 016-9977-0

568 Lorenzen E., Dalsgaards I. & Bernardet J-F. (1997) Characterization of isolates of
569 *Flavobacterium psychrophilum* associated with coldwater disease or rainbow trout fry
570 syndrome I: phenotypic and genomic studies. *Diseases of Aquatic Organisms* **31**, 197-
571 208.

572 Michel C., Kerouault B. & Martin C. (2003) Chloramphenicol and florfenicol
573 susceptibility of fish-pathogenic bacteria isolated in France: comparison of minimum
574 inhibitory concentration, using recommended provisory standards for fish bacteria.
575 *Journal of Applied Microbiology* **95**, 1008-1015.

576 Miller R.A. & Reimschuessel R. (2006) Epidemiologic cutoff values for antimicrobial
577 agents against *Aeromonas salmonicida* isolates determined by frequency distributions of
578 minimal inhibitory concentration and diameter of zone of inhibition data. *American*
579 *Journal of Veterinary Research* **67**, 1837-1843.

580 Minoque E., Barry T. Carroll C. & Smith P. (2013) Setting epidemiological cut-off
581 values for *Aeromonas salmonicida* disc diffusion data capable of discriminating between
582 strains on the basis of their possession of *sulI* genes. *Aquaculture* **364-365**, 329-332.

583 Miranda C.D, Smith P., Rojas R., Contreras-Lynch S. & Alonso Vega J.M. (2016)
584 Antimicrobial susceptibility of *Flavobacterium psychrophilum* from Chilean salmon
585 farms and their epidemiological cut-off values using agar dilution and disk diffusion
586 methods. *Frontiers in Microbiology*. Doi: 10.3389/fmicb.2016.01880.

587 Ngo T.P.H., Bartie K.L., Thompson K.D., Verner-Jeffreys D.W., Hoare R. & Adams A.
588 (2017) Genetic and serological diversity of *Flavobacterium psychrophilum* isolates from
589 salmonids in United Kingdom. *Veterinary Microbiology*. Doi:
590 10.1016/j.vetmic.2017.01.032

591 Nilsen H., Johansen R., Colquhoun D.J., Kaada I., Bottolfsen K., Vågnes Ø. & Olsen A.
592 B. (2011) *Flavobacterium psychrophilum* associated with septicaemia and necrotic
593 myositis in Atlantic salmon *Salmo salar*: a case report. *Diseases of Aquatic Organisms*
594 **97**, 37-46.

595 Pacha R.E. (1968) Characteristics of *Cytophaga psychrophila* (Borg) isolated during
596 outbreaks of bacterial cold-water disease. *Applied Microbiology* **16**, 97-101.

597 Prescott J. F. (2007) Sulfonamides, diaminopyrimidines, and their combinations. In:
598 Antimicrobial Therapy in Veterinary Medicine 4th edition, Wiley-Blackwell, pp. 249-262
599 Rangdale R.E., Richards R.H. & Alderman D.J. (1997) Minimum inhibitory
600 concentrations of selected antimicrobial compounds against *Flavobacterium*
601 *psychrophilum* the causal agent of rainbow trout fry syndrome (RTFS). *Aquaculture* **158**,
602 193-201.

603 Romero J., Feijó C. G. & Navarrete P. (2012) Antibiotics in aquaculture – use, abuse
604 and alternatives. In Health and Environment in Aquaculture, InTech, 159-198.

605 Schmidt A.S., Bruun M.S., Dalsgaard I., Pedersen K. & Larsen J.L. (2000) Occurrence of
606 antimicrobial resistance in fish-pathogenic and environmental bacteria associated with
607 four Danish rainbow trout farms. *Applied and Environmental Microbiology* **66**, 4908-
608 4915.

609 Silley P. (2012) Susceptibility testing methods, resistance and breakpoints: what do these
610 terms really mean? *Scientific and Technical Review of the Office International des*
611 *Epizooties* **31**, 33-41.

612 Smith, P. (2008). “Antimicrobial resistance in aquaculture” in *Changing Trends in*
613 *Managing Aquatic Animal Disease Emergencies*, ed. E.-M. Bernoth (Paris: OIE), **27**,
614 243–264.

615 Smith P. & Kronvall G. (2014) Estimating the precision of disc diffusion antibiotic
616 susceptibility data published by the European Committee on Antimicrobial Susceptibility
617 Testing. *APMIS* DOI: 10.1111/am.12262 (in press).

618 Smith P. & Kronvall G. (2015) Effect of incubation temperature and time on the
619 precision of data generated by antibiotic disc diffusion assays. *Journal of Fish Diseases*
620 **38**, 629-536.

621 Smith P, Ruane N.M., Douglas I., Carroll C., Kronvall G. & Flemming G.T.A. (2007)
622 Impact of inter-lab variation on the estimation of epidemiological cut-off values for disc
623 diffusion susceptibility test data for *Aeromonas salmonicida*. *Aquaculture* **272**, 168-179.

624 Smith P., Schwarz T. & Verner-Jeffreys DW. (2012). Use of normalised resistance
625 analyses to set interpretive criteria for antibiotic disc diffusion data produce by
626 *Aeromonas* spp. *Aquaculture* **326–329**, 27-35.

627 Smith P., Alday-Sanz V., Matysczak J., Moulin G., Lavilla-Pitogo C.R. & Prater D.
628 (2013) Monitoring and surveillance of antimicrobial resistance in mircoorganisms
629 associated with aquatic animals. *Scientific and Technical Review* **32**, 583-593.

630 Smith P., Endris R., Kronvall G., Thomas V., Verner-Jeffreys D., Wilhelm C. &
631 Dalsgaard I. (2016) Epidemiological cut-off values for *Flavobacterium psychrophilum*
632 MIC data generated by a standard test protocol. *Journal of Fish Diseases* **39**, 143-154.

633 Soltani M., Shanker S. & Munday B.L. (1995) Chemithrapy of *Cytophaga/Flecibacter*-
634 like bacteria (CFLB) infections in fish: studies validating clinical efficacies of selected
635 antimicrobials. *Journal of Fish Diseases* **18**, 555-565.

636 Soule M., Lafrentz S., Cain K., Lapatra S. & Call D.R. (2005) Polymorphisms in 16S
637 rRNA genes of *Flavobacterium psychrophilum* correlate with elastin hydrolysis and
638 tetracycline resistance. *Diseases of Aquatic Organisms* **65**, 209-216.

639 Stenholm A.R., Dalsgaard I. & Middelboe M. (2008) Isolation and characterization of
640 bacteriophages infecting the fish pathogen *Flavobacterium psychrophilum*. *Applied and*
641 *Environmental Microbiology* **74**, 4070-4078.

642 Ström- Bestor M. & Wiklund T. (2011) Inhibitory activity of *Pseudomonas* sp. on
643 *Flavobacterium psychrophilum*, *in vitro*. *Journal of Fish Diseases* **34**, 255-264.

644 Sundell K., Heinikainen S. & Wiklund T. (2013) Structure of *Flavobacterium*
645 *psychrophilum* populations infecting farmed rainbow trout *Oncorhynchus mykiss*.
646 *Diseases of Aquatic Organisms* **103**, 111-119.

647 Toyama T., Kita-Tsukamoto K. & Wakabayashi H. (1994) Identification of *Cytophaga*
648 *psychrophila* by PCR targeted 16S ribosomal RNA. *Fish Pathology* **29**, 271-275.

649 Valdebenito S. & Avendaño-Herrera R. (2009) Phenotypic, serological and genetic
650 characterization of *Flavobacterium psychrophilum* strains isolated from salmonids in
651 Chile. *Journal of Fish Diseases* **32**, 321-333.

652 Van Vliet D., Loch T.P., Smith P. & Faisal M. (2017) Antimicrobial susceptibilities of
653 *Flavobacterium psychrophilum* isolates from the Great Lakes Basin, Michigan. *Microbial*
654 *Drug Resistance*. Doi:10.1089/mdr.2016.0103.

655 Verner-Jeffreys D.W. & Taylor N.J. (2015) Review of freshwater treatments used in the
656 Scottish freshwater rainbow trout aquaculture industry. *Scottish Aquaculture Research*
657 *Forum Report SARF100*

658 Verner-Jeffreys, D.W., Brazier, T., Perez, R.Y., Ryder, D., Card, R.M., Welch, T.J.,
659 Hoare, R., Ngo, T., MacLaren, N., Ellis, R., Bartie, K.L., Feist, S.W., Rowe, W.M.P.,
660 Adams, A. & Thompson, K.D. (2017) Detection of the florfenicol resistance gene *floR* in

661 *Chryseobacterium* isolates from rainbow trout. Exception to the general rule? *FEMS*

662 *Microbiol Ecol.* Doi: 10.1093/femsec/fix015.

663

664 **Table 1.** Summary of 118 UK *F. psychrophilum* isolates analysed in this study

Location	Host source	No. of sites	Site	Year of isolation	No. of sampling times	No. of strains	No. of genotypes (*)	No. of plasmid profiles (*)
<i>Scotland</i>	<i>RT(93)/AS(14)</i>	<i>20</i>		<i>2005-2015</i>	<i>46</i>	<i>102</i>	<i>47</i>	<i>7</i>
			Scot I	2005-2014	16	25	11	4
			Scot II	2013	1	1	1	1
			Scot III	2011-2015	4	13	9	4
			Scot IV	2013	1	5	2	2
			Scot V	2013-2015	4	27	16	5
			Scot VI	2009	1	1	1	1
			Scot VII	2007	1	1	1	1
			Scot VIII	2005	1	1	1	1
			Scot IX	2006	1	1	1	1
			Scot X	2011-2013	2	3	2	1
			Scot XI	2015	1	4	3	1
			Scot XII	2010	1	1	1	1
			Scot XIII	2005	1	1	1	1
			Scot XIV	2013	1	2	1	1
			Scot XV	2013	2	3	2	1
			Scot XVI	2014-2015	4	9	4	3
			Scot XVII	2007	1	1	1	1
			Scot XVIII	2009	1	1	1	1
			Unknown (2)	2009-2012	2	2	2	2
<i>England</i>	<i>RT</i>	<i>6</i>		<i>2007-2015</i>	<i>8</i>	<i>13</i>	<i>5</i>	<i>2</i>
			Eng I	2013	3	8	4	2
			Eng II	2015	1	1	1	1
			Eng III	2015	1	1	1	1
			Eng IV	2015	1	1	1	1
			Eng V	2007	1	1	1	1
			Eng VI	2007	1	1	1	1
<i>Northern Ireland</i>	<i>RT</i>	<i>1</i>	<i>N Ire I</i>	<i>2013</i>	<i>2</i>	<i>3</i>	<i>2</i>	<i>2</i>
Total	RT(111)/AS(14)			2005-2015	56	118	51	7

665 RT, rainbow trout; AS, Atlantic salmon
666 (*) Genotypes and plasmid profiles of *F. psychrophilum* isolates determined by Ngo *et al.* (2017).
667
668

669 **Table 2.** Fifteen *F. psychrophilum* isolates from outside the UK used in this study
670

Countries	Host source	Year of isolation	No. of strains	No. of genotypes ^a	No. of plasmid profiles ^a
Chile	RT	1995-1997	2	2	2
Denmark	RT	1990-1994	3	3	1
Finland	RT	1996	2	2	1
France	RT	unknown-2013	3	2	1
Ireland	AS	2006	1	1	1
USA ^b	RT(3)/CS(1)	unknown - 2004	4	4	2
Total	RT(13)/AS(1)/CS(1)	unknown - 2013	15	13	3

671 RT, rainbow trout; AS, Atlantic salmon; CS, coho salmon
672 ^a Pulsotypes and plasmid profiles of *F. psychrophilum* isolates determined by Ngo *et al.* (2017).
673 ^b including the *F. psychrophilum* type strain NCIMB 1947^T
674
675

676 **Table 3.** MIC values (mg L⁻¹) determined for 133 *F. psychrophilum* isolates

	Off scale	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	Off scale
β lactams																
AMOX	93										19	13	8			
AMP	24						66	3			15	17	8			
Macrolides																
ERY	4									4	24	93	8			
Phenicol																
FFN								1	9	69	54					
Quinolones																
ENRO				7	10	3	3	51	17	14	28					
FLUQ						3	16	1	1	3	41	13	13			42
OXO							7	13	1	1	6	47				58
Tetracyclines																
OTC						12	40	4		2		7	33	32		3
	Off scale	0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	Off scale

677 Shaded areas indicate MIC values could not be determined using Sensititre CMP1MSP plates.
678 Off scale indicates the number of strains whose MIC lay outside of the range that could be determined using these plates.
679
680

681 **Table 4.** MIC values (mg L⁻¹) determined for potentiated sulphonamide drugs against 133 *F. psychrophilum* isolates
682

	Off scale	0.008/0.15	0.015/0.30	0.03/0.59	0.06/1.19	0.12/2.38	0.25/4.75	0.5/9.5	1/19	2/38	4/76	Off scale
PRI						1	2	15	28	43	29	15
SXT					1	11	37	30	48			6

683
684 Shaded areas indicate MIC values could not be determined using Sensititre CMP1MSP plates.

685 Table 5. Cut-off values (CO_{WT}) calculated using NRI from 133 MIC observations

Agent	Number of WT observations	Standard deviation ^a (log ₂ mg L ⁻¹)	CO _{WT} (mg L ⁻¹)
AMP ^b	93 (70%)	ND ^c	≤ 0.125
ENRO	20 (15%)	0.74	≤ 0.032
ERY	133 (100%)	0.98	≤ 8
FFN	133 (100%)	0.68	≤ 2
FLUQ	20 (15%)	0.57	≤ 0.125
OTC	56 (42%)	0.68	≤ 0.25
OXO	21 (16%)	0.67	≤ 0.25
PRI	133 (100%)	1.39	≤ 16/304
SXT	133 (100%)	1.61	≤ 8/152

686 ^a Standard deviation of the normalised distribution of MIC values for WT strains.





687 ^b CO_{WT} value of AMP was estimated by visual examination.

688 ^c ND: not determined

691 Table 6. Provisional cut-off values (CO_{WT}) calculated using NRI from 133 inhibition zone
692 observations

Agent	Number of WT observations	Standard deviation* (mm)	CO _{WT} (mm)
AMOX ₁₀	90 (68%)	5.20	≥56
FFN ₃₀	133 (100%)	5.61	≥45
OTC ₃₀	65 (49%)	7.44	≥51
OXO ₂	20 (15%)	8.50	≥30

693 * Standard deviation of the normalised distribution of MIC values for WT strains.






Figure 1. Distribution of 133 *F. psychrophilum* strains according to inhibition zone diameters generated by disc diffusion method for 30 µg oxytetracycline (A, OTC₃₀), 10 µg amoxicillin (B, AMOX₁₀), 30 µg florfenicol (C, FFN₃₀), 2 µg oxolinic acid (D, OXO₂), 5 µg enrofloxacin (E, ENRO₅) and 25 µg trimethoprim/sulphamethoxazole (F, SXT₂₅). The continuous line represents the 8 point rolling means, the vertical dashed line represents the calculated disc diffusion-based cut-off value.




Figure 2. Plot of 133 paired MIC values versus disc diffusion zone diameters for oxytetracycline (A), florfenicol (B) and oxolinic acid (C). A continuous thick line presents the calculated cut-off line of the microbial agent.




Figure 3. Plot of 133 paired MIC values between antimicrobial agents within beta-lactam group (A: ampicillin and amoxicillin) and quinolone group (B: oxolinic acid and flumequine; C: oxolinic acid and enrofloxacin). A continuous thick line presents the calculated cut-off line of the microbial agent. A dashed line presents an estimated cut-off value.